Exploring Nectin-4 as a potential diagnostic biomarker in endometrial adenocarcinoma: Title page

Creative Commons License

Ordu M., GENÇ Ş. Ö.

BMC Women's Health, cilt.26, sa.1, 2026 (SCI-Expanded, SSCI, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1186/s12905-025-04227-8
  • Dergi Adı: BMC Women's Health
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals
  • Anahtar Kelimeler: Endometrial adenocarcinoma, Immunohistochemistry, Mismatch repair proteins, Nectin-4, P53
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Background: This study explored Nectin-4 expression in endometrial adenocarcinoma and examined its relationship with tumor grade, hormone receptor status, p53 expression, and mismatch repair (MMR) protein expression. Methods: We retrospectively analyzed 55 paraffin-embedded tissue samples collected between 2015 and 2023, including endometrial adenocarcinoma, endometrial intraepithelial neoplasia (EIN), and normal endometrium samples. Nectin-4 expression was assessed via immunohistochemistry, and correlations with clinicopathological features and molecular markers were evaluated statistically. Results: Nectin-4 expression increased with histological grade (p < 0.001). All Grade III tumors presented strong expression, whereas lower-grade tumors presented variable staining. The expression of these genes was also correlated with p53 overexpression (p = 0.007) and PMS2 loss (p = 0.002). Nectin-4 was absent in normal tissues and weakly expressed in EIN. Conclusion: Nectin-4 expression is linked to high-grade endometrial carcinoma and abnormal p53 expression, supporting its potential role as a diagnostic biomarker. Larger studies are needed to validate its clinical use.